Not sure if my readers have noticed it, but Big Pharma has drastically increased their bashing of aspirin since the pandemic started. Those attacks began when a few studies published back in 2020 demonstrated that aspirin users had a much lower risk of both contracting and dying from COVID-19, and that aspirin was unique among NSAID in providing such benefits. The bashing of aspirin continues even in the study below, but it is forced to (begrudgingly) admit that low-dose aspirin led to 15% lower risk of developing diabetes in older adults. Now, 15% reduction may not seem like much, but so far there has been no other drug shown to lower risk of developing diabetes. Also, these effects were seen from low-dose aspirin and the pro-metabolic effects of aspirin are known to be dose-dependent (e.g. uncoupling and inhibition of both lipolysis / fatty acid oxidation), so higher doses would have likely led to much bigger risk reduction. Of course, the fear-mongering from Big Pharma about aspirin’s dire bleeding risks effectively prevents human trials with higher doses, so unfortunately aspirin probably won’t see much clinical use as prevention/therapy for diabetes.
https://medicalxpress.com/news/2023-08-low-dose-aspirin-diabetes-people-aged.html
“…A total of 16,209 participants were included in the analysis (8,086 randomized to aspirin and 8,123 to placebo). Over a median follow-up of 4.7 years, 995 incident diabetes cases were recorded (aspirin: 459, placebo: 536). Compared with placebo, the aspirin group had a 15% reduction in incident diabetes and a slower rate of increase in FPG (difference in annual FPG change: -0.006 mmol/L). The authors say, “Aspirin treatment reduced incident diabetes and slowed the increase in fasting plasma glucose over time among initially healthy older adults. Given the increasing prevalence of type 2 diabetes among older adults, the potential for anti-inflammatory agents like aspirin to prevent type 2 diabetes or improve glucose levels needs further study.””
